# Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition

> **NCT05231798** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Down Syndrome
- Down Syndrome, Partial Trisomy 21
- Alzheimer Disease

## Interventions

- **DRUG:** [18F]-FEOBV Radiotracer

## Key facts

- **NCT ID:** NCT05231798
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-19
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05231798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05231798, "Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05231798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*